SAN FRANCISCO, Nov. 14 – Myriad Genetics will market its predictive medicine products in Brazil through Sao Paulo-based Fleury Laboratories, the companies announced Wednesday.

The initial products marketed in Brazil from the Salt Lake City-based company will be cancer prediction kits, including ones to detect mutations for types of breast, skin, and colon cancer.

Financial details of the agreement were not disclosed.

Fleury Laboratories has 1,300 employees and 15 clinics throughout Brazil, according to the company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.